TabletsClinical Overview
Levonorgestrel Tablet IP 1.5 mg is a synthetic second-generation progestogen emergency contraceptive on the WHO Model List of Essential Medicines. When administered during the pre-ovulatory phase, it prevents or delays the LH surge and subsequent follicular rupture/ovulation; it also impairs sperm motility and thickens cervical mucus. Indicated as an emergency post-coital contraceptive within 72 hours (3 days) of unprotected sexual intercourse or known contraceptive failure (e.g. condom breakage, missed pills). It is NOT an abortifacient and will not terminate an established pregnancy.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally one 1.5 mg tablet with water as soon as possible, preferably within 12 hours and no later than 72 hours (3 days) after unprotected sexual intercourse. Can be taken with or without food. If vomiting occurs within 2 hours of ingestion, a replacement tablet must be taken immediately. Normal menses usually occurs within 7 days of expected date.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Nausea, fatigue, lower abdominal pain, headache, dizziness, breast tenderness, and menstrual irregularities (menses may arrive a few days earlier or later, with spotting). Rare/Severe: Ectopic pregnancy risk if failure occurs, severe pelvic pain, and allergic reactions.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Intended strictly for occasional emergency use; NOT intended as a routine contraceptive method. Does not protect against HIV or STIs. Contraindicated in confirmed pregnancy (ineffective) and undiagnosed abnormal vaginal bleeding. If menses is delayed by more than 7 days, take a pregnancy test.
Schedule H / OTC (Emergency Contraception)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Gynecological, Obstetric & Endocrinological Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice or reproductive healthcare guidance. Hormonal medications, uterotonics, corticosteroids, fertility therapies, and emergency contraceptives have profound systemic actions and must be administered strictly under the supervision of a registered gynecologist, obstetrician, or endocrinologist.
Ethinylestradiol 0.05mg + Levonorgestrel 0.25mg Tablets
Ethinylestradiol and Levonorgestrel Tablets IP is a second-generation low-dose Combined Oral Contraceptive (COC) pill on the WHO Model List of Essential Medicines. It synergistically suppresses the mid-cycle LH surge to inhibit ovulation, renders cervical mucus hostile to sperm migration, and alters the endometrium. Second-generation levonorgestrel combinations demonstrate the lowest epidemiological relative risk of venous thromboembolism among combined oral contraceptives. Indicated for prevention of pregnancy, cycle regulation, and treatment of dysmenorrhea.
Ethinylestradiol 0.03mg + Levonorgestrel 0.15mg Tablets
Ethinylestradiol and Levonorgestrel Tablets IP is a second-generation low-dose Combined Oral Contraceptive (COC) pill on the WHO Model List of Essential Medicines. It synergistically suppresses the mid-cycle LH surge to inhibit ovulation, renders cervical mucus hostile to sperm migration, and alters the endometrium. Second-generation levonorgestrel combinations demonstrate the lowest epidemiological relative risk of venous thromboembolism among combined oral contraceptives. Indicated for prevention of pregnancy, cycle regulation, and treatment of dysmenorrhea.